ASCO GU 2024 Kidney Cancer

Viewing 1-20 of 23 articles

ASCO GU 2024: Update on Biomarkers in Renal Cell Carcinoma

ASCO GU 2024: Genetic Testing in RCC: Who, When, and How?

ASCO GU 2024: Management of Non-Clear Cell Renal Cell Carcinoma

ASCO GU 2024: The Emergent Role of Theranostics in Renal Cell Carcinoma

ASCO GU 2024: Belzutifan Versus Everolimus in Participants With Previously Treated Advanced Renal Cell Carcinoma: Patient-Reported Outcomes in the Phase 3 LITESPARK-005 Study

ASCO GU 2024: Insights from CheckMate 67T and Patient-Reported Outcomes in LITESPARK-005 for Advanced RCC

ASCO GU 2024: The Role of Radiation in Primary Tumor and Distant Sites in Managing Renal Cell Carcinoma

ASCO GU 2024: Subcutaneous Nivolumab Versus Intravenous Nivolumab in Patients With Previously Treated Advanced or Metastatic Clear Cell Renal Cell Carcinoma: Pharmacokinetics, Efficacy, and Safety Results From CheckMate 67T

ASCO GU 2024: Phase III Randomized Trial of Stereotactic Ablative Radiotherapy for Oligometastatic Advanced Renal Carcinoma (EA8211-SOAR)

ASCO GU 2024: First-in-Human Safety, Imaging and Dosimetry of [68Ga]Ga-DPI-4452, a Novel CA IX-Targeting Peptide, in Patients with Clear Cell RCC

ASCO GU 2024: Subgroup Analyses of Efficacy Outcomes by Baseline Tumor Size in the Phase 3, Open-label CLEAR Trial

ASCO GU 2024: Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) analysis

ASCO GU 2024: Phase 1b/2 Study of Combination 177Lu Girentuximab plus Cabozantinib and Nivolumab in Treatment Naive Patients with Advanced Clear Cell RCC

ASCO GU 2024: Development of a Patient-Centered HRQOL Measure for Metastatic RCC: A Three-Phase Study

ASCO GU 2024: Nivolumab plus Ipilimumab vs Sunitinib for First-Line Treatment of Advanced RCC: Long-Term Follow-up Data from the Phase 3 CheckMate 214 Trial

ASCO GU 2024: Nivolumab plus Cabozantinib vs Sunitinib for Previously Untreated Advanced RCC: Results from 55-Month Follow-up of the CheckMate 9ER Trial

ASCO GU 2024: The Impact of Immunotherapy-Based Regimens in Primary Renal Tumors

ASCO GU 2024: First-line Pembrolizumab plus Lenvatinib for Non–clear Cell RCC: Extended Follow-up of the Phase 2 KEYNOTE-B61 Study

ASCO GU 2024: The Role of Cytoreductive Nephrectomy in the Immune Checkpoint Inhibitor Era of Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-Analysis of 2319 Patients

ASCO GU 2024: Evaluating Intermediate Endpoints for Overall Survival in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors: An IMDC Study

1
2